RECURRENT GLIOBLASTOMA MULTIFORME: IMPLICATION OF NONENHANCING LESIONS ON BEVACIZUMAB TREATMENT

被引：0
|
作者：
Alexandru, Daniela [1 ]
Bota, Daniela [1 ]
Linskey, Mark E. [1 ]
机构：
[1] UCI Med Ctr, Orange, CA USA
来源：
NEURO-ONCOLOGY | 2011年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：143 / 143
页数：1
相关论文
共 50 条
  • [21] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
    Raval, S.
    Hwang, S.
    Dorsett, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme
    Zhang, Guobin
    Huang, Shengyue
    Wang, Zhongcheng
    JOURNAL OF CLINICAL NEUROSCIENCE, 2012, 19 (12) : 1636 - 1640
  • [23] PROLONGED REMISSION OF GLIOBLASTOMA MULTIFORME WITH BEVACIZUMAB AND IRINOTECAN TREATMENT
    Nagaiah, Govardhanan
    Almubarak, Mohammed
    Torres-Trejo, Alejandro
    Newton, Michael
    Willey, Paige
    Altaha, Ramin
    NEURO-ONCOLOGY, 2010, 12 : 5 - 5
  • [24] Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab
    Wagle, Naveed
    Nghiemphu, Leia
    Lai, Albert
    Pope, Whitney
    Mischel, Paul S.
    Cloughesy, Timothy
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2010, 3 : 79 - 85
  • [25] Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
    Sathornsumetee, S.
    Vredenburgh, J. J.
    Rich, J. N.
    Desjardins, A.
    Quinn, J. A.
    Mathe, A. E.
    Gururangan, S.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Bevacizumab appears active against recurrent glioblastoma multiforme: A case series
    Hasson, Ahmed
    Fathallah-Shaykh, Hassan M.
    NEUROLOGY, 2008, 70 (11) : A297 - A297
  • [27] PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Reardon, David A.
    Sathornsumetee, Sith
    Vredenburgh, James J.
    Rich, Jeremy N.
    Desjardins, Annick
    Quinn, Jennifer A.
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allen H.
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2009, 11 (02) : 231 - 231
  • [28] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [29] Bevacizumab-induced hypertension correlation with survival in recurrent glioblastoma multiforme
    Tavares, N. T.
    Simoes, J.
    Borges, C.
    Meireles, S.
    Costa, A.
    Fernandes, C.
    Caeiro, C.
    Damasceno, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] Severe periocular bleeding induced by bevacizumab in a patient with recurrent glioblastoma multiforme
    Eryilmaz, Melek K.
    Mutlu, Hasan
    Musri, Fatma Yalcin
    Salim, Derya K.
    Tazegul, Gokhan
    Coskun, Hasan S.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (05) : 392 - 395
12345